Uniphore Unveils Enhanced Interaction Analytics Solution Powered by Generative AI
21.3.2024 16:41:00 EET | Business Wire | Press release
Uniphore, one of the world’s largest AI-native companies, announced a major upgrade to its U-Analyze analytics solution, which builds on the company’s industry-leading multimodal enterprise AI platform to help customers effectively access data and power their AI needs.
This new generative AI-fueled version of U-Analyze directly addresses a growing need among global enterprises to leverage the power of AI and their own data. Drawing from customer conversations across text, voice and video, business leaders can make knowledgeable, timely, data-driven decisions to revolutionize their customers’ experiences as well as agent performance.
This announcement is a deliberate next step following the introduction of Uniphore’s groundbreaking U Capture, an AI-native solution that aids customers’ ability to capture, structure and apply a full suite of multimodal data --- powered by the company’s X-Platform. A key benefit for customers includes the ownership and accessibility of their own data whenever they need it, to drive additional value.
Bolstered by Uniphore’s powerful X-Platform, U-Analyze works seamlessly with U-Capture to analyze conversational data in real time and generate unique AI-driven insights for each enterprise. The insights, along with the automated and manual coaching capabilities, allow enterprises to continuously improve customer experiences and engagement. Ultimately, U-Analyze will help enterprises predict and adapt to customer and market needs.
When you combine the power of the two solutions, the analytics provide timely AI-generated insights that have the potential to dramatically improve customer satisfaction and engagement.
“Analytics will never be the same with Uniphore’s enterprise-grade AI platform transforming the way our customers are able to harness the power and value of data,” said Umesh Sachdev, CEO and Co founder of Uniphore. “This is a significant milestone in Uniphore’s unwavering commitment to our global enterprise customers on their journey to becoming AI-led companies.”
A recent global survey of over 500 contact center leaders sponsored by Uniphore underscored the need for AI-driven insights. For example, nearly 40% of respondents said they lack the data to respond quickly to business decisions or improve their customers’ experiences. Also, 86% said the decisions they make are not predominantly data-driven, reinforcing the massive opportunity for business leaders and enterprises to put their own data to use.
“Enterprise organizations are hungry for better insights – and better conversational analytics solutions. Traditional analytics solutions don’t necessarily include the technologies driving the current wave of innovation in the enterprise – including generative AI and knowledge AI,” said Hayley Sutherland, Research Manager, Conversational AI & Intelligent Knowledge Discovery at IDC. “With these upgrades to U-Analyze, Uniphore is keeping on the cutting edge of such innovations and helping organizations move the needle when it comes to AI-driven actionable insights based on customer interactions, which could have a big impact on business processes and results.”
Uniphore will be at Enterprise Connect at the Gaylord Palms in Orlando, Florida from March 25-28, 2024 at booth 306 in the AI Innovation Zone.
For additional information on the U and Q product lines, please click here.
To stay up to date with the latest commentary, follow our blog, or connect with us on LinkedIn, X, Facebook, or Instagram.
About Uniphore
Uniphore is one of the largest B2B AI-native companies – decades-proven, built-for-scale, and designed for the Enterprise. The company drives business outcomes, across multiple industry verticals, and the largest global deployments. Uniphore infuses AI into every part of the Enterprise that impacts the customer. We deliver the only multimodal AI architecture centered on customers that combines Generative AI, Knowledge AI and Emotion AI and Workflow Automation and a co-pilot to guide you. We understand better than anyone how to capture voice, video, text, and how to analyze all types of data. As AI becomes more powerful, every part of the Enterprise that impacts the customer will be disrupted. We believe the future will run on the connective tissue between people, machines and data: all in service of creating the most human processes and experiences for customers and employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321078876/en/
Contact information
For more information, please contact: pr@uniphore.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
